6 900 diagnostic exams (including 3 090 PET)
121 patients have been treated: - including 55 with thyroid cancer - and 34 with liver cancer
Missions The major missions of the Medical Imaging Department are
To provide high quality diagnostic and therapeutic services using radioactive elements.
To carry out translational and early clinical research, with a particular focus on new targeted treatments.
To deliver high quality pre- and postgraduate teaching in nuclear oncology.
To integrate imaging into the multidisciplinary oriented approach to patient care.
the development of imaging from structural to molecular and the ongoing integration of molecular Dr MArCW LeMOrt, Head of Medical imaging Department
50 groups from Europe, Canada, Latin America, Asia and Australasia
Several 1,000 specialised hospitals and research centres worldwide
> 30 clinical trials with 10s of thousands of patients
BREAST INTERNATIONAL GROUP (BIG)
DePartMental organisation Founded in 1996 by Dr Martine Piccart from the Institute together with other European opinion leaders, BIG now constitutes a network of 50 groups from Europe, Canada, Latin America, Asia and Australasia linked to several thousand specialised hospitals and cancer research centres. BIG also works closely with the US National Cancer Institute and the North American Breast Cancer Group.
More than 30 clinical trials are run under the BIG umbrella, involving 10s of thousands of patients. Although a leader in large adjuvant trials of chemo-, hormone- and biological therapy, BIG is also a trailblazer for research in other areas, including programmes supported by the European Commission and neoadjuvant trials. BIG trials incorporate a substantial translational research component and emphasise the collection and banking of biological specimens for future research.
Jointly with the European Society for Medical Oncology, BIG hosts an annual breast cancer conference – IMPAKT – focused on improving care and knowledge through translational research. The event gathers leading preclinical and clinical researchers and provides training for early career researchers (www.impakt.org).
Dr Phuong Dinh Medical Oncologist, Scientiﬁc Director
Carolyn Straehle Managing Director Missions
Supporting international collaboration to conduct studies that would not be possible for a single research group or network to carry out on its own, especially as treatments become increasingly targeted
Combining efforts to quickly enrol large numbers of patients and to share data and knowledge to efﬁciently answer important scientiﬁc questions
biG is unique in its capacity to unite academic groups from arou world to c duct breast c ncer research in way that best serves the needs of patients. CArOLyn StrAeHLe, Managing Director, biG
Main areas BIG is a non-proﬁt organisation for academic breast cancer research groups from around the world, with its headquarters at the Institute.
BIG facilitates breast cancer research by stimulating cooperation between its members and other academic networks, and by striving to achieve balanced partnerships between academia and industry in order to best serve the needs of patients.